U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...

Company behind weight loss drug Mounjaro, Lilly, has issued an official statement after British woman, Susan McGowan, died ...

The United Kingdom will study whether the use of weight loss drugs could get people back to work. UK Health Minister Wes ...

The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

Despite the success of its new weight loss drug Zepbound, Lilly's recent earnings failed to meet expectations.